The synthetic biology firm maintains its 2026 cash burn guidance while scaling its Nebula platform to 105 robotic automation cells.
Ginkgo Bioworks reaffirmed its 2026 cash burn guidance of $125M to $150M during its Q2 2026 earnings call. The company emphasized continued investment in autonomous labs to strengthen its market position in the sector.
Management previously outlined the cash burn range in earlier guidance, aligning with its strategy to expand capacity. The Nebula platform’s expansion to 105 robotic automation cells reflects efforts to scale operations without adjusting financial projections.
No immediate market reaction was disclosed in the call summary.